Alphamab Oncology executives buy shares, CEO exercises options

Alphamab Oncology's executive director and senior management purchased 900,000 shares between July 14-16 at an average price of HK$7.257.

Separately, chief executive Dr. Xu Ting exercised 9,005,890 options on July 16 at HK$0.1109 under the pre-IPO share option plan, following a previous exercise of 4,552,950 options in May 2020.